Showing posts with label VEGFR2. Show all posts
Showing posts with label VEGFR2. Show all posts
Saturday, July 17, 2010
Abstract/full acess: Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
Background: Hypertension (HT) and hand-foot skin reactions (HFSR) may be related to the activity of bevacizumab and sorafenib. We hypothesized that these toxicities would correspond to favorable outcome in these drugs, that HT and HFSR would coincide, and that VEGFR2 genotypic variation would be related to toxicity and clinical outcomes.
METHODS
Patients and treatment
The analyses were performed on genomic DNA from 178 patients (143 males and 35 females) with solid tumors who received sorafenib (VEGFR2 inhibitor) and/or bevacizumab (anti-VEGF) with or without other agents....cont'd (excerpt from pdf file)
Conclusions: This study suggests that HT and HFSR may be markers for favorable clinical outcome, HT development may be a marker for HFSR, and VEGFR2 alleles may be related to the development of toxicities during therapy with bevacizumab and/or sorafenib.
add your opinions
Avastin
,
Bevacizumab
,
hand foot syndrome
,
hypertension
,
outcomes
,
Sorafenib
,
toxicity
,
VEGFR2
Wednesday, June 09, 2010
Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells
Note: ACOR members see notes from Chicago
Abstract (in research/technical):
"Our findings highlight the possible confounding events that may affect the usefulness of RNAi in a therapeutic setting for disrupting EOC cell survival in ascites."
Subscribe to:
Posts
(
Atom
)